[Physiological anticoagulants. Current data on the composition, function and clinical value].

Z S Barkagan; K M Bishevskii

Home/Archive/PubMed

PubMed · 81906

[Physiological anticoagulants. Current data on the composition, function and clinical value].

Z S Barkagan·K M Bishevskii

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Antithrombin III Antithrombin III Deficiency Blood Transfusion Complement C1 Inactivator Proteins Fibrinolysis Heparin Humans Sphingomyelins Thromboplastin alpha 1-Antitrypsin alpha-Macroglobulins English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Z S Barkagan, K M Bishevskii. 1978. [Physiological anticoagulants. Current data on the composition, function and clinical value].. https://pubmed.ncbi.nlm.nih.gov/81906/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Prolonged coagulation instability is associated with a higher-dose regimen of tissue-type plasminogen activator in patients with acute myocardial infarction.

Explore the source record for details and available documents.

Antithrombin III↗

PubMed1992

[Antithrombin III. Structure, pathophysiology, determination and therapeutic importance].

The article is devoted to the coagulation proteinases inhibitor antithrombin III which plays an important role in the processes of blood coagulation. The molecular and gene structure, physiology and pathophysiology, assays and therapeutical meanings are dealt with.

Antithrombin III↗

PubMed1992

Two new nonsense mutations in type Ia antithrombin III deficiency at Leu 140 and Arg 197.

Using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and DNA sequencing, the molecular basis of hereditary type Ia antithrombin III (AT III) deficiency was disclosed in two families. One mutation was a change from T to A in the codon of TTA for Leu 140 forming a stop codon of TAA, which was confirmed by mutated primer-mediated PCR-HindIII digestion. The application of this method demonstrated that all four affected members had the mutant allele in a heterozygous state and that none of unaffected subjects had this mutation. Another mutation in the second family was a change from C to T in the codon of CGA for Arg 197 also forming a stop codon of TGA, which was confirmed by PCR-HaeIII digestion. Based on these, it was concluded that the two new nonsense mutations in the AT III gene in a heterozygous state are the molecular basis of hereditary type Ia AT III deficiency.

Antithrombin III↗